Liposarcoma Treatment Market lucrative opportunities by 2022 examined in new market research report

Liposarcoma is a cancer of fat cells lying deep within the soft tissues, typically in retroperitoneum or thighs. According to WHO, liposarcoma is the most common type of sarcomas (cancer of soft tissue) and accounts for approximately 17-20% of all cases of sarcoma. However, WHO classifies liposarcoma in the rare diseases as the incidence rate of the disease is as low as 2.5 per Mn population. Liposarcoma most commonly occurs in the middle age or adults above the age of 40 and it can be well diagnosed with the help of excision biopsy. Liposarcoma can be of four types viz. well differentiated liposarcoma, myxoid liposarcoma, pleomorphic liposarcoma and dedifferentiated liposarcoma. The most common drugs used for the treatment of liposarcoma include ifosfamide and doxorubicin. Ifosfamide is often prescribed in combination with uromitexan in order to prevent bladder irritation and internal bleeding. Moreover, cisplatin, vincristine, etoposide, gemcitabine, docetaxel etc. can be used to prevent the recurrence of liposarcoma.

The market for liposarcoma is highly fragmented with large number of generic manufacturers. The global market for liposarcoma treatment is expected to grow moderately over the forecast period owing to low incidence rate of the disease. Some other factors which are anticipated to influence growth of global liposarcoma treatment market include lifestyle changes, incidence of genetic disorders, growing awareness through liposarcoma genome project etc. However, high cost of the treatment can be the major restraint for the growth of global liposarcoma treatment market.

For detailed insights on enhancing your product footprint, request for a Sample here @

The global liposarcoma treatment market has been classified on the basis of treatment type, end user and geography.

Based on treatment type, the global liposarcoma treatment market is divided into following:

  • Chemotherapy
  • Radiation Therapy
  • Surgical Therapy

Based on the end user type, the global liposarcoma treatment market is divided into following:

  • Hospitals
  • Multispecialty Clinics
  • Cancer treatment and rehabilitation centers

Surgical therapy treatment segment is expected to account for major share in global liposarcoma treatment market as it is the choice of treatment recommended by majority of cancer specialists. Most of the physicians do not rely on chemotherapy for the liposarcoma treatment however, it can be used prior to the surgery to reduce the size of the tumor making it the second largest segment in terms of value in global liposarcoma treatment market. Radiation therapy treatment is used to avoid recurrence of the liposarcoma after surgery and contributes a minimal share in global liposarcoma treatment market.

Geographically, global liposarcoma treatment market is classified into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is anticipated to lead the global liposarcoma treatment market due to relatively greater prevalence of the disease in the region. APAC and MEA regions are expected to witness steady market growth owing to lack of awareness about the disease.

To receive extensive list of important regions, ask for TOC here @

Some of the key players in global liposarcoma treatment market include:

  • Eli Lilly and Company
  • Baxter International
  • Bristol Laboratories Ltd.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Actavis plc.
  • Fresenius Kabi Ltd.
  • Accord Healthcare Inc.
  • Taro Pharmaceuticals Inc.
  • Sandoz
  • Bedford Laboratories

Recently FDA approved the new indication of Halaven (eribulin) to Esai Co. Ltd. and new drug application of Yondelis (Trabectedin) from Johnson & Johnson Private Limited for use in Europe, Russia and South Korea.

Recommended For You

About the Author:

Leave a Reply

Your email address will not be published. Required fields are marked *